|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||5.32 - 5.42|
|52 Week Range||4.79 - 10.80|
|PE Ratio (TTM)||-1.24|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||9.13|
Eli Lilly • LLY-NYSE Long-Term Buy • Price $82.17 on Sept. 12 by Hilliard Lyons At the European Society for Medical Oncology Annual Congress, Lilly presented strong data from a key trial on its cancer drug Abemaciclib. As a reminder to investors, while cross-trial comparisons are difficult to make, the presentation provided physicians and investors the best opportunity to compare Abemaciclib to the other CDK4/6 inhibitors, and we think it can take some market share from competitors in this niche.
NEW YORK , Sept. 11, 2017 /PRNewswire/ -- Iconix Brand Group, Inc. (Nasdaq: ICON) ("Iconix" or the "Company"), today announced that its Chief Financial Officer, Dave Jones is scheduled ...
The consumer-products specialist surprised investors with weak second-quarter results.